News related to Vinorelbine and/or conditions it is approved for
FDA Approves New Lung Cancer Diagnostic "Cobas EGFR Mutation Test"
Source: Cancer / Oncology News From Medical News Today [2013.05.15]
The U.S. Food and Drug Administration (FDA) has approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10 percent of non-small cell lung cancers (NSCLC)...
ASCO: More Radiation No Good in NSCLC
Source: MedPage Today Oncology/Hematology [2013.05.15]
CHICAGO (MedPage Today) -- Boosting the dose of radiation therapy in stage III non-small cell lung cancer actually compromises outcomes and cuts survival, a randomized trial showed.
FDA Approves Companion Genetic Diagnostic Test for Tarceva
Source: Medscape Today Headlines [2013.05.14]
The FDA has approved the first companion diagnostic test that can detect EGFR mutations in non-small cell lung cancer.
FDA Approvals
FDA OKs Test for Use with Tarceva
Source: MedPage Today Oncology/Hematology [2013.05.14]
WASHINGTON (MedPage Today) -- The FDA has approved a companion EGFR mutation test for use with the targeted cancer drug erlotinib (Tarceva) to help guide decision making in non-small cell lung cancer.
Lung Cancer Survival Improved By Chemo, Radiation, Then Surgery
Source: Lung Cancer News From Medical News Today [2013.05.02]
In one of the largest observational studies of its kind, researchers report that a combination of chemotherapy and radiation followed by surgery in patients with stage 3 non-small cell lung cancer improves survival. Patients who had chemoradiation therapy followed by surgery had twice the five-year survival rate of those who had only chemoradiation, says Dr...
Patients With Lung Cancer Who Carry Specific HER2 Mutations May Benefit From Certain Anti-HER2 Treatments
Source: Lung Cancer News From Medical News Today [2013.04.24]
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations...
Experts Examine Profiles From Patients With Early Stage Lung Adenocarcinoma, Identify Patterns Of Mutations To Help Inform Design Of Future Trials
Source: Clinical Trials / Drug Trials News From Medical News Today [2013.03.26]
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer (NSCLC), surgical resection remains the treatment of choice with adjuvant chemotherapy...
Lung Cancer: Expanded Alimta Label
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has expanded the indication for the cancer drug pemetrexed injection to act as a maintenance therapy with cisplatin for nonsquamous non-small cell lung cancer.
|
